Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

February 9, 2022

Study Completion Date

May 28, 2025

Conditions
Mantle Cell Lymphoma (MCL)
Interventions
DRUG

Ibrutinib

Capsule; Oral

DRUG

Venetoclax

Tablet; Oral

Trial Locations (12)

9808574

Tohoku University Hospital /ID# 221975, Sendai

460-0001

NHO Nagoya Medical Center /ID# 221958, Nagoya

464-8681

Aichi Cancer Center Hospital /ID# 221565, Nagoya

812-8582

Kyushu University Hospital /ID# 223299, Fukuoka

060-8648

Hokkaido University Hospital /ID# 221662, Sapporo

650-0047

Kobe City Medical Center General Hospital /ID# 221744, Kobe

311-3193

National Hospital Organization Mito Medical Center /ID# 224912, Higashi Ibaraki-gun

920-8530

Ishikawa Prefectural Central Hospital /ID# 224896, Kanazawa

700-8558

Duplicate_Okayama University Hospital /ID# 221623, Okayama

350-8550

Saitama Medical Center /ID# 224910, Kawagoe-shi

104-0045

National Cancer Center Hospital /ID# 221812, Chuo-ku

990-9585

Yamagata University Hospital /ID# 221573, Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY